Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2021 10:06 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil

COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil.Commercialization in progress with...
September 27, 2021 13:13 ET | Source: Sorrento Therapeutics, Inc.

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the Cantor Virtual Healthcare Conference. Dr Henry...
August 26, 2021 12:28 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device

Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th of the dose vs an LNP-mRNA reference standard1 (“LNP-mRNA”) delivered...
August 24, 2021 10:44 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University

MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.MPro inhibitors block this catalytic process to potentially inhibit the viral...
August 11, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
August 09, 2021 14:39 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat...
August 04, 2021 12:57 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), in collaboration with The Scripps Research Institute of La Jolla, today announced that the...
July 21, 2021 14:09 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors

Anti-TROP-2 coupled to SN38 (a DNA polymerase inhibitor) (ESG-401) has received approval to begin clinical trials.ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors,...
July 20, 2021 09:00 ET | Source: Sorrento Therapeutics, Inc.

Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter

China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
July 06, 2021 14:34 ET | Source: Sorrento Therapeutics, Inc.

FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...

Next Page keyboard_arrow_right